News

Overview

WuXi News

2020/10/29

WuXi AppTec Reports Strong Third-Quarter 2020 Results

SHANGHAI, Oct. 29, 2020 /PRNewswire/ -- WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, is pleased to announce its financial results for the third quarter and nine months ended September 30, 2020 ("Reporting Period").

Read more

2020/08/13

WuXi AppTec Achieved Strong Growth in First-Half of 2020 with China Sites Resuming Full Operations

(SHANGHAI, August 13, 2020) — WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, is pleased to announce its reviewed financial results for the first half of 2020 (Reporting Period).

Read more

2020/06/01

WuXi AppTec Appoints Dr. David Chang as CEO of WuXi Advanced Therapies Business Unit

SHANGHAI and PHILADELPHIA, June 1, 2020 -- WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, announced today the appointment of Dr. David Chang as Chief Executive Officer of WuXi Advanced Therapies business unit (WuXi ATU), WuXi AppTec’s cell and gene therapy Contract Development and Manufacturing Organization (CDMO). In this new executive role, Dr. Chang will provide strategic, scientific and operational leadership to the company’s global cell and gene therapy R&D and manufacturing services.

Read more

Innovation that Matters

2020/10/27

Cydan Sets the Pace for Rare Disease R&D

October 6, 2020 As part of our ongoing interest in rare disease R&D, we interviewed Niels Svenstrup, the Senior Vice President of Development at Cydan, a virtual rare disease accelerator focused on the development of treatments for rare genetic disorders. Tune in to hear discussion on Cydan’s unique disease –agnostic model and their prosperous child orphan drug companies, Imara and Tiburio. Gain insight into the future of rare disease R&D, Cydan’s essential collaborations, and more. We invite you to watch now.

Read more

2020/10/27

Galera Therapeutics, Reducing Toxicity & Increasing Anti-Cancer Efficacy for Patients

September 8, 2020 Dr. Robert Beardsley, Founder and Chief Operating Officer at Galera Therapeutics, shares his company’s R&D vision and pipeline, aimed at improving treatments and outcomes for cancer patients. Recently, Galera’s lead product candidate, avasopasem manganese (GC4419) received Fast Track and Breakthrough Therapy Designations for the reduced incidence and severity of severe oral mucositis (SOM) – a common painful side effect experienced by 70% of head and neck cancer patients undergoing radiotherapy.   Tune in to hear more on Galera’s pipeline, the science behind small molecule dismutase mimetics, Robert’s insights for the future, and the partnerships enhancing Galera’s success. Watch now. 

Read more

2020/09/01

Big Ideas Yield Transformative Results for SMA Patients

As part of this year’s SMA Awareness month, we interviewed Stuart Peltz, the Founder and CEO of PTC Therapeutics. He shares his company’s R&D journey that led to the approval of Evrysdi™ (risdiplam), the first-ever oral treatment for spinal muscular atrophy. The drug received accelerated approval in August 2020 by the FDA and has been recognized as a breakthrough treatment for adults and children two months and older suffering from the disease. In this interview, Stuart discusses the challenges of developing the drug and how it was made possible – including insights into PTC Therapeutics’ partnerships with Roche and the SMA Foundation. Watch now.  

Read more